Capstone Investment Advisors
AMRX icon

Capstone Investment Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Capstone Investment Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,762
Closed -$168K – 1567
2025
Q3 		$168K Sell
16,762
-27,999
-63% -$251K ﹤0.01% 1853
2025
Q2 		$362K Buy
+44,761
New +$337K ﹤0.01% 1296

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Capstone Investment Advisors's AMRX Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2025, closing a stake of 16,762 shares — an estimated $168K sold.

Capstone Investment Advisors first reported a position in AMRX in Q2 2025 and held it in 2 quarters. The position peaked at $362K in Q2 2025. 277 funds tracked by Wall St. Rank hold AMRX as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 16,762 Amneal Pharmaceuticals shares in Q4 2025, an estimated $168K.
  • Capstone Investment Advisors first reported a position in Amneal Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Capstone Investment Advisors's Amneal Pharmaceuticals position peaked at $362K in Q2 2025.
  • 277 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.